Literature DB >> 10467360

Adenoviral vectors for in vivo gene delivery to oligodendrocytes: transgene expression and cytopathic consequences.

R m Franklin1, M m Quick, G Haase.   

Abstract

Replication defective viral vectors provide a potentially useful means of gene transfer to oligodendrocytes and thus for studying the pathogenesis of white matter disease. In this study we have examined the expression pattern of E1/E3 deleted adenoviral vectors expressing the reporter gene LacZ (AdlacZ) as a means of establishing the value of these vectors for gene delivery to oligodendrocytes in adult rat white matter. Our results indicate that although such an approach can be used to induce transgene expression in oligodendrocytes, it is complicated by both immunogenic and cytopathic effects. Thus, in normal animals, injection of DeltaE1/E3 adenoviral vectors was associated with a robust immune response that led to a lack of expression by 40 days after injection. In order to overcome this complication, virus was injected into the white matter of immuno-deficient athymic rats. These experiments indi- cated that even in the absence of a T cell response high viral titres of DeltaE1/E3 adenoviral vectors had a profound cytopathic effect leading to death of oligodendrocytes and hence demyelination. A similar cytopathic effect was demonstrated using an adenoviral vector expressing the neurocytokine ciliary neurotrophic factor (AdCNTF). As the titre of injected virus was decreased there was a significant decrease in the number of transgene expressing cells. These experiments therefore indicated that in immunodeficient recipients there is a narrow window of virus titre that results in a high rate of infectivity and expression without significant cytopathic consequences. At higher viral titres the cytopathic effects include oligodendrocyte death and demyelination, while at lower titres there is a significant decrease in the efficiency of the number of cells expressing the transgene.

Entities:  

Mesh:

Year:  1999        PMID: 10467360     DOI: 10.1038/sj.gt.3300971

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  4 in total

Review 1.  Gene Therapy: The Next-Generation Therapeutics and Their Delivery Approaches for Neurological Disorders.

Authors:  Abhik Paul; Michael G Collins; Hye Young Lee
Journal:  Front Genome Ed       Date:  2022-06-22

2.  Gene delivery into malignant glioma by infectivity-enhanced adenovirus: in vivo versus in vitro models.

Authors:  Winan J Van Houdt; Hongju Wu; Joel N Glasgow; Martine L Lamfers; Clemens M Dirven; G Yancey Gillespie; David T Curiel; Yosef S Haviv
Journal:  Neuro Oncol       Date:  2007-05-23       Impact factor: 12.300

3.  Development of an RNA Virus-Based Episomal Vector Capable of Switching Transgene Expression.

Authors:  Yusuke Yamamoto; Keizo Tomonaga; Tomoyuki Honda
Journal:  Front Microbiol       Date:  2019-11-06       Impact factor: 5.640

4.  Significant alterations of biodistribution and immune responses in Balb/c mice administered with adenovirus targeted to CD40(+) cells.

Authors:  D Huang; A V Pereboev; N Korokhov; R He; L Larocque; C Gravel; B Jaentschke; M Tocchi; W L Casley; M Lemieux; D T Curiel; W Chen; X Li
Journal:  Gene Ther       Date:  2007-11-29       Impact factor: 5.250

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.